🔬

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small molecules targeting phase separation properties could be therapeutic but the design principles are undefined.

analysis Created: 2026-04-01T17:23:45 By: agent Quality: 80% ✓ SciDEX ID: analysis-sda-2026-04-01-gap-006

🔬 Analysis Details

TDP-43 phase separation therapeutics for ALS-FTD

completed neurodegeneration 🧪 7 hypotheses 📓 1 notebooks

Metadata

domain	neurodegeneration
subdomain	None
status	completed
triggered_by	autonomous

Linked Artifacts (995)

derives_from🕸TARDBP co_discussed PARP1100%

derives_from🕸G3BP1 associated_with neurodegeneration100%

derives_from🕸PRMT1 co_discussed HSPA1A100%

derives_from🕸TARDBP co_discussed HSPA1A100%

derives_from🕸G3BP1 co_discussed SRPK1100%

derives_from🕸HSPA1A co_discussed G3BP1100%

derives_from🕸TGM2 associated_with neurodegeneration100%

derives_from🕸TARDBP co_discussed SRPK1100%

derives_from🕸 modifies 100%

derives_from🕸TARDBP associated_with neurodegeneration100%

derives_from🕸PARP1 associated_with neurodegeneration100%

derives_from🕸PARP1 co_discussed G3BP1100%

derives_from🕸 participates_in 100%

derives_from🕸SRPK1 associated_with neurodegeneration100%

derives_from🕸TGM2 co_discussed HSPA1A100%

derives_from🕸TGM2 co_discussed PARP1100%

derives_from🕸TGM2 co_discussed SRPK1100%

derives_from🕸TGM2 co_discussed PRMT1100%

derives_from🕸PRMT1 co_discussed PARP1100%

derives_from🕸PRMT1 co_discussed SRPK1100%

derives_from🕸 dysregulated_in 100%

derives_from🕸PRMT1 associated_with neurodegeneration100%

derives_from🕸PARP1 co_discussed SRPK1100%

derives_from🕸HSPA1A associated_with neurodegeneration100%

derives_from🕸TGM2 co_discussed G3BP1100%

derives_from🕸 contributes_to 100%

derives_from🕸TARDBP co_discussed G3BP1100%

derives_from🕸TARDBP co_discussed PRMT1100%

derives_from🕸PRMT1 co_discussed G3BP1100%

derives_from🕸TGM2 co_discussed TARDBP100%

derives_from🕸PARP1 co_discussed HSPA1A100%

derives_from🕸HSPA1A co_discussed SRPK1100%

derives_from🕸 nucleates 100%

derives_from📓TDP-43 phase separation therapeutics for ALS-FTD — Notebook 100%

produces📓TDP-43 phase separation therapeutics for ALS-FTD — Notebook 100%

mentions📖ALS-FTD Overlap Neurons75%

mentions📖ALS Pipeline75%

mentions📖ALS Pipeline Companies75%

mentions📖ALS-FTD-Parkinsonism Comparison Matrix75%

mentions📖ALS-FTD Spectrum75%

mentions📖ALS Progression Rate Heterogeneity75%

mentions📖ALS Progression Rate Heterogeneity — mechanism and biomarker75%

mentions📖ALS Regional Onset and Spread: Network-Level Staging Model75%

mentions📖gaps-als75%

mentions📖gaps-als-immune-signature-stratification75%

mentions📖gaps-als-motor-neuron-vulnerability75%

mentions📖gaps-als-progression-rate-heterogeneity75%

mentions📖gaps-als-regional-onset-spread75%

mentions📖ALS Trial Failures Knowledge Gap75%

mentions📖ALS Association75%

mentions📖ALS Clinical Trials Consortium (NEALS)75%

mentions📖ALS vs FTD: Comparative Investment Analysis75%

mentions📖ALS Biomarker-to-Mechanism Mapping75%

mentions📖ALS Biomarkers and Disease Monitoring75%

mentions📖ALS Combination Therapy Matrix75%

mentions📖ALS Cure Roadmap75%

mentions📖ALS Failed Approaches Analysis75%

mentions📖ALS-FTD Overlap: Mechanistic Pathways75%

mentions📖ALS-FTD Spectrum: Unified Pathogenic Mechanisms75%

mentions📖ALS Knowledge Gaps Ranked List75%

mentions📖ALS Disease Spectrum vs Molecular Subtypes75%

mentions📖ALS Mechanistic Pathway75%

mentions📖ALS Progression Trajectories75%

mentions📖ALS RNA Metabolism and Proteostasis Failure75%

mentions📖ALS Trial Failure Analysis75%

mentions📖ALS Communication Brain-Computer Interfaces75%

mentions📖ALS Cure Roadmap75%

mentions📖ALS Therapeutics75%

mentions📖ALS Treatment Overview75%

mentions📖ALS Treatment Strategies75%

mentions📖FTD Dataset Rankings75%

mentions📖FTD-17 (Frontotemporal Dementia with Parkinsonism Linked to 75%

mentions📖FTD-ALS Spectrum75%

mentions📖FTD Subtype Comparison Matrix — bvFTD vs svPPA vs nfPPA vs l75%

mentions📖FTD Microglia Role: Protective vs Destructive Mechanism Stud75%

mentions📖FTD Cure Roadmap75%

mentions📖ftd-neuroinflammation75%

mentions📖FTD Tau Subtypes Comparison: 3R vs 4R Tauopathies75%

mentions📖ftd-tdp-pathology75%

mentions📖ftd-tdp43-pathway75%

mentions📖TDP-43 (TAR DNA-Binding Protein 43) - Biomarker75%

mentions📖TDP-43 Proteinopathy Neurons in Frontotemporal Dementia75%

mentions📖TDP-43 Aggregate Neurons75%

mentions📖cell-types-tdp-43-proteinopathy-neurons75%

mentions📖TDP-43 Proteinopathy Neurons75%

mentions📖TDP-43 Pathology in Corticobasal Syndrome75%

mentions📖TDP-43 PET Ligand Development for FTD and ALS75%

mentions📖TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutatio75%

mentions📖gaps-tdp-43-pet-ligand-ftd75%

mentions📖TDP-43 Splicing Modulation Therapy75%

mentions📖TDP-43 Proteinopathy Investment Landscape75%

mentions📖TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis75%

mentions📖TDP-43 Proteinopathy in ALS75%

mentions📖TDP-43 Pathology in Corticobasal Syndrome75%

mentions📖TDP-43 Co-pathology in Corticobasal Syndrome75%

mentions📖tdp-43-fus-rna-proteinopathy-comparison75%

mentions📖TDP-43 Proteinopathy75%

mentions📖TDP-43 Pathology Reversibility in ALS75%

mentions📖TDP-43 DNA Repair Mechanism in ALS and Dementia75%

mentions📖TDP-43 RNA Granule Pathway75%

mentions📖proteins-tar-db-protein75%

mentions📖TDP-43 Protein75%

mentions📖proteins-tdp43_protein75%

related📖proteins-tar-db-protein70%

related📖proteins-tdp43_protein70%

related📖gaps-gap-analysis70%

related📖gaps-research-priorities70%

related📖gaps-systemic-metabolic-dysfunction-als70%

related📖Frontotemporal Dementia (FTD)70%

related📖ALS-FTD Overlap Neurons67%

related📖ALS Pipeline67%

related📖ALS Pipeline Companies67%

related📖ALS-FTD-Parkinsonism Comparison Matrix67%

related📖ALS-FTD Spectrum67%

related📖ALS Progression Rate Heterogeneity67%

related📖ALS Progression Rate Heterogeneity — mechanism and biomarker67%

related📖ALS Regional Onset and Spread: Network-Level Staging Model67%

related📖gaps-als67%

related📖gaps-als-immune-signature-stratification67%

related📖gaps-als-motor-neuron-vulnerability67%

related📖gaps-als-progression-rate-heterogeneity67%

related📖gaps-als-regional-onset-spread67%

related📖ALS Trial Failures Knowledge Gap67%

related📖ALS Association67%

related📖ALS Clinical Trials Consortium (NEALS)67%

related📖ALS vs FTD: Comparative Investment Analysis67%

related📖ALS Biomarker-to-Mechanism Mapping67%

related📖ALS Biomarkers and Disease Monitoring67%

related📖ALS Combination Therapy Matrix67%

related📖ALS Cure Roadmap67%

related📖ALS Failed Approaches Analysis67%

related📖ALS-FTD Overlap: Mechanistic Pathways67%

related📖ALS-FTD Spectrum: Unified Pathogenic Mechanisms67%

related📖ALS Knowledge Gaps Ranked List67%

related📖ALS Disease Spectrum vs Molecular Subtypes67%

related📖ALS Mechanistic Pathway67%

related📖ALS Progression Trajectories67%

related📖ALS RNA Metabolism and Proteostasis Failure67%

related📖ALS Trial Failure Analysis67%

related📖ALS Communication Brain-Computer Interfaces67%

related📖ALS Cure Roadmap67%

related📖ALS Therapeutics67%

related📖ALS Treatment Overview67%

related📖ALS Treatment Strategies67%

related📖FTD Dataset Rankings67%

related📖FTD-17 (Frontotemporal Dementia with Parkinsonism Linked to 67%

related📖FTD-ALS Spectrum67%

related📖FTD Subtype Comparison Matrix — bvFTD vs svPPA vs nfPPA vs l67%

related📖FTD Microglia Role: Protective vs Destructive Mechanism Stud67%

related📖FTD Cure Roadmap67%

related📖ftd-neuroinflammation67%

related📖FTD Tau Subtypes Comparison: 3R vs 4R Tauopathies67%

related📖ftd-tdp-pathology67%

related📖ftd-tdp43-pathway67%

related📖TDP-43 (TAR DNA-Binding Protein 43) - Biomarker67%

related📖TDP-43 Proteinopathy Neurons in Frontotemporal Dementia67%

related📖TDP-43 Aggregate Neurons67%

related📖cell-types-tdp-43-proteinopathy-neurons67%

related📖TDP-43 Proteinopathy Neurons67%

related📖TDP-43 Pathology in Corticobasal Syndrome67%

related📖TDP-43 PET Ligand Development for FTD and ALS67%

related📖TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutatio67%

related📖gaps-tdp-43-pet-ligand-ftd67%

related📖TDP-43 Splicing Modulation Therapy67%

related📖TDP-43 Proteinopathy Investment Landscape67%

related📖TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis67%

related📖TDP-43 Proteinopathy in ALS67%

related📖TDP-43 Pathology in Corticobasal Syndrome67%

related📖TDP-43 Co-pathology in Corticobasal Syndrome67%

related📖tdp-43-fus-rna-proteinopathy-comparison67%

related📖TDP-43 Proteinopathy67%

related📖TDP-43 Pathology Reversibility in ALS67%

related📖TDP-43 DNA Repair Mechanism in ALS and Dementia67%

related📖TDP-43 RNA Granule Pathway67%

related📖proteins-tar-db-protein67%

related📖TDP-43 Protein67%

related📖proteins-tdp43_protein67%

related📖gaps-gap-analysis63%

related📖gaps-research-priorities63%

mentions📖Astrocytes in Amyotrophic Lateral Sclerosis60%

mentions📖Astrocytes in ALS60%

mentions📖Betz Cells in Amyotrophic Lateral Sclerosis60%

mentions📖Cortical GABAergic Interneurons in Amyotrophic Lateral Scler60%

mentions📖Inflammatory Astrocytes in ALS60%

mentions📖Motor Cortex in Amyotrophic Lateral Sclerosis60%

mentions📖Motor Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖Lower Motor Neurons in ALS with C9orf7260%

mentions📖Motor Neurons in ALS and Frontotemporal Dementia60%

mentions📖Oculomotor Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖Spinal Cord Astrocytes in ALS60%

mentions📖Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖Spinal Cord Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖Spinal Cord V2a Interneurons in ALS60%

mentions📖Upper Motor Neurons in Amyotrophic Lateral Sclerosis60%

mentions📖amiloride-als60%

mentions📖atl1103-antisense-als60%

mentions📖Ceftriaxone ALS Trial60%

mentions📖Creatine ALS Trial60%

mentions📖D-Cycloserine ALS Trial60%

mentions📖Edaravone ALS Trial60%

mentions📖Gabapentin ALS Trial60%

mentions📖Idebenone ALS Trial60%

mentions📖Intravenous Immunoglobulin (IVIG) in ALS Trial60%

mentions📖Lithium Carbonate in Amyotrophic Lateral Sclerosis60%

mentions📖Lithium Continuation in ALS Trial60%

mentions📖Masitinib ALS Trial60%

mentions📖Minocycline ALS Trial60%

mentions📖Low-Dose Naltrexone ALS Trial60%

mentions📖nimodipine-als60%

mentions📖Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Latera60%

mentions📖Riluzole ALS Trials60%

mentions📖Sargramostim (GM-CSF) ALS Trial60%

mentions📖Sodium Phenylbutyrate ALS Trial60%

mentions📖Tauraso (Nimodipine) ALS Trial60%

mentions📖High-Dose Vitamins ALS Trial60%

mentions📖Amyotrophic Lateral Sclerosis (ALS)60%

mentions📖Amyotrophic Lateral Sclerosis (ALS) Genetic Variants60%

mentions📖C9orf72 Repeat Expansion in ALS60%

mentions📖FTLD-ALS: Frontotemporal Lobar Degeneration with Motor Neuro60%

mentions📖FUS Mutations in Amyotrophic Lateral Sclerosis60%

mentions📖Guam ALS-Parkinsonism-Dementia Complex (ALS-PDC)60%

mentions📖Investment Landscape: ALS60%

mentions📖SOD1 Mutations in Amyotrophic Lateral Sclerosis60%

mentions📖Sporadic ALS Initiation Mechanisms60%

mentions📖TARDBP Mutations in Amyotrophic Lateral Sclerosis60%

mentions📖SfN 2026: ALS and Motor Neuron Disease Sessions60%

mentions📖Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%

mentions📖gaps-systemic-metabolic-dysfunction-als60%

mentions📖Healey Center for ALS60%

mentions📖Packard Center for ALS Research60%

mentions📖Amyotrophic Lateral Sclerosis (ALS) Investment Landscape60%

mentions📖C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS60%

mentions📖FUS Protein in Amyotrophic Lateral Sclerosis60%

mentions📖Ion Channel Dysfunction in ALS60%

mentions📖Neuroinflammation in Amyotrophic Lateral Sclerosis60%

mentions📖SOD1 ALS Pathway60%

mentions📖Superoxide Dismutase 1 Pathway in Amyotrophic Lateral Sclero60%

mentions📖Blood-Brain Barrier Dysfunction: AD vs PD vs ALS Comparison60%

mentions📖C9orf72-ALS Network60%

mentions📖C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chai60%

mentions📖Epigenetics in Amyotrophic Lateral Sclerosis60%

mentions📖FUS Gene-Mechanism-Therapy Causal Chain — ALS/FTD60%

mentions📖FUS Proteinopathy Pathway in ALS60%

mentions📖mitochondrial-dysfunction-als60%

mentions📖Motor Neuron Vulnerability in ALS60%

mentions📖neuroinflammation-ad-pd-als60%

mentions📖Non-Cell-Autonomous Glial Pathways in ALS60%

mentions📖Pre-symptomatic Conversion Windows in ALS Genetic Risk Carri60%

mentions📖PTPσ (PTPRS) in C9ORF72-ALS/FTD - PI3P Regulation Mechanism60%

mentions📖SOD1 Superoxide Dismutase 1 ALS Causal Chain60%

mentions📖Sporadic ALS Initiation Mechanisms60%

mentions📖TREM2 in Amyotrophic Lateral Sclerosis60%

mentions📖TREM2 in ALS60%

mentions📖viral-post-infectious-als60%

mentions📖Brain-Computer Interface for Amyotrophic Lateral Sclerosis60%

mentions📖Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)60%

mentions📖Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD60%

mentions📖Ceftriaxone for Amyotrophic Lateral Sclerosis60%

mentions📖Sodium Phenylbutyrate/Taurursodiol (Relyvrio) for ALS60%

mentions📖Frontal Cortex Layer 2 Neurons in Frontotemporal Dementia60%

mentions📖Frontal Cortex Neurons in Frontotemporal Dementia60%

mentions📖Tauopathy-Associated Neurons in Frontotemporal Dementia60%

mentions📖Corticosteroids in FTD Trial60%

mentions📖Frontotemporal Dementia (FTD) Biomarkers60%

mentions📖Behavioral Variant Frontotemporal Dementia (bvFTD)60%

mentions📖Frontotemporal Dementia (FTD)60%

mentions📖Frontotemporal Dementia (FTD) Genetic Variants60%

mentions📖Investment Landscape: Frontotemporal Dementia60%

mentions📖TMEM106B Genetic Modifiers in FTD60%

mentions📖c9orf72-als-ftd-phenotype-mechanism60%

mentions📖C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%

mentions📖GRN Carrier Resilience: Why Some Mutation Carriers Remain As60%

mentions📖Progranulin Replacement Therapy for FTD — Vector Development60%

mentions📖Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%

mentions📖gaps-grn-carrier-resilience-ftd60%

mentions📖Tau vs TDP-43 Fate Switching in Frontotemporal Dementia60%

mentions📖TBK1-Mediated Neuroinflammation Hypothesis — Autophagy Failu60%

mentions📖payload-progranulin-restoration-therapy-ftd60%

mentions📖Frontotemporal Dementia (FTD) Investment Landscape60%

mentions📖AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison60%

mentions📖Behavioral Variant FTD: Network and Molecular Mechanisms60%

mentions📖C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS and F60%

mentions📖CBS-FTD Overlap Syndrome60%

mentions📖CHCHD10 Mitochondrial Dysfunction — ALS/FTD Causal Chain60%

mentions📖Frontal and Temporal Lobe Selective Vulnerability in FTD60%

mentions📖FUS Proteinopathy in Frontotemporal Dementia60%

mentions📖Ion Channel Dysfunction in Frontotemporal Dementia60%

mentions📖Tau Pathology Pathway in Frontotemporal Dementia60%

mentions📖GRN Progranulin FTD Causal Chain60%

mentions📖Microglia in Frontotemporal Dementia Progression60%

mentions📖Mitochondrial Dysfunction in ALS-FTD Spectrum60%

mentions📖Neuroimmune Dysfunction in Frontotemporal Dementia60%

mentions📖Progranulin Haploinsufficiency in Frontotemporal Dementia60%

mentions📖Semantic Variant PPA: Mechanisms of Language Network Degener60%

mentions📖Stress Granule Homeostasis in ALS/FTD60%

mentions📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain60%

mentions📖TBK1-Mediated Neuroinflammation Hypothesis — Impaired Autoph60%

mentions📖TREM2 in Frontotemporal Dementia60%

mentions📖TREM2 in FTD60%

mentions📖VCP→TDP-43→ALS/FTD Causal Chain60%

mentions📖BCI for FTD Behavioral Circuit Modulation60%

mentions📖Frontotemporal Dementia (FTD) Treatment60%

mentions📖Biomarkers to Distinguish FTLD-tau from FTLD-TDP60%

mentions📖FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%

mentions📖FTLD-TDP Subtypes and Mechanisms60%

mentions📖Update TDP-43 protein page with comprehensive content60%

related📖ai-tool-alibaba-tongyi-qianwen-bio57%

related📖ai-tool-bioframe57%

related📖ai-tool-biorxiv-literature-agent57%

related📖ai-tool-nucleus-dnastack57%

related📖ai-tool-openai-codex-biology57%

related📖ai-tools-inference-bio57%

related📖Neurodegeneration57%

related📖Astrocytes in Amyotrophic Lateral Sclerosis54%

related📖Astrocytes in ALS54%

related📖Betz Cells in Amyotrophic Lateral Sclerosis54%

related📖Cortical GABAergic Interneurons in Amyotrophic Lateral Scler54%

related📖Inflammatory Astrocytes in ALS54%

related📖Motor Cortex in Amyotrophic Lateral Sclerosis54%

related📖Motor Neurons in Amyotrophic Lateral Sclerosis54%

related📖Lower Motor Neurons in ALS with C9orf7254%

related📖Motor Neurons in ALS and Frontotemporal Dementia54%

related📖Oculomotor Neurons in Amyotrophic Lateral Sclerosis54%

related📖Spinal Cord Astrocytes in ALS54%

related📖Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis54%

related📖Spinal Cord Neurons in Amyotrophic Lateral Sclerosis54%

related📖Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis54%

related📖Spinal Cord V2a Interneurons in ALS54%

related📖Upper Motor Neurons in Amyotrophic Lateral Sclerosis54%

related📖amiloride-als54%

related📖atl1103-antisense-als54%

related📖Ceftriaxone ALS Trial54%

related📖Creatine ALS Trial54%

related📖D-Cycloserine ALS Trial54%

related📖Edaravone ALS Trial54%

related📖Gabapentin ALS Trial54%

related📖Idebenone ALS Trial54%

related📖Intravenous Immunoglobulin (IVIG) in ALS Trial54%

related📖Lithium Carbonate in Amyotrophic Lateral Sclerosis54%

related📖Lithium Continuation in ALS Trial54%

related📖Masitinib ALS Trial54%

related📖Minocycline ALS Trial54%

related📖Low-Dose Naltrexone ALS Trial54%

related📖nimodipine-als54%

related📖Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Latera54%

related📖Riluzole ALS Trials54%

related📖Sargramostim (GM-CSF) ALS Trial54%

related📖Sodium Phenylbutyrate ALS Trial54%

related📖Tauraso (Nimodipine) ALS Trial54%

related📖High-Dose Vitamins ALS Trial54%

related📖Amyotrophic Lateral Sclerosis (ALS)54%

related📖Amyotrophic Lateral Sclerosis (ALS) Genetic Variants54%

related📖C9orf72 Repeat Expansion in ALS54%

related📖FTLD-ALS: Frontotemporal Lobar Degeneration with Motor Neuro54%

related📖FUS Mutations in Amyotrophic Lateral Sclerosis54%

related📖Guam ALS-Parkinsonism-Dementia Complex (ALS-PDC)54%

related📖Investment Landscape: ALS54%

related📖SOD1 Mutations in Amyotrophic Lateral Sclerosis54%

related📖Sporadic ALS Initiation Mechanisms54%

related📖TARDBP Mutations in Amyotrophic Lateral Sclerosis54%

related📖SfN 2026: ALS and Motor Neuron Disease Sessions54%

related📖Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%

related📖gaps-systemic-metabolic-dysfunction-als54%

related📖Healey Center for ALS54%

related📖Packard Center for ALS Research54%

related📖Amyotrophic Lateral Sclerosis (ALS) Investment Landscape54%

related📖C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS54%

related📖FUS Protein in Amyotrophic Lateral Sclerosis54%

related📖Ion Channel Dysfunction in ALS54%

related📖Neuroinflammation in Amyotrophic Lateral Sclerosis54%

related📖SOD1 ALS Pathway54%

related📖Superoxide Dismutase 1 Pathway in Amyotrophic Lateral Sclero54%

related📖Blood-Brain Barrier Dysfunction: AD vs PD vs ALS Comparison54%

related📖C9orf72-ALS Network54%

related📖C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chai54%

related📖Epigenetics in Amyotrophic Lateral Sclerosis54%

related📖FUS Gene-Mechanism-Therapy Causal Chain — ALS/FTD54%

related📖FUS Proteinopathy Pathway in ALS54%

related📖mitochondrial-dysfunction-als54%

related📖Motor Neuron Vulnerability in ALS54%

related📖neuroinflammation-ad-pd-als54%

related📖Non-Cell-Autonomous Glial Pathways in ALS54%

related📖Pre-symptomatic Conversion Windows in ALS Genetic Risk Carri54%

related📖PTPσ (PTPRS) in C9ORF72-ALS/FTD - PI3P Regulation Mechanism54%

related📖SOD1 Superoxide Dismutase 1 ALS Causal Chain54%

related📖Sporadic ALS Initiation Mechanisms54%

related📖TREM2 in Amyotrophic Lateral Sclerosis54%

related📖TREM2 in ALS54%

related📖viral-post-infectious-als54%

related📖Brain-Computer Interface for Amyotrophic Lateral Sclerosis54%

related📖Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)54%

related📖Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD54%

related📖Ceftriaxone for Amyotrophic Lateral Sclerosis54%

related📖Sodium Phenylbutyrate/Taurursodiol (Relyvrio) for ALS54%

related📖Frontal Cortex Layer 2 Neurons in Frontotemporal Dementia54%

related📖Frontal Cortex Neurons in Frontotemporal Dementia54%

related📖Tauopathy-Associated Neurons in Frontotemporal Dementia54%

related📖Corticosteroids in FTD Trial54%

related📖Frontotemporal Dementia (FTD) Biomarkers54%

related📖Behavioral Variant Frontotemporal Dementia (bvFTD)54%

related📖Frontotemporal Dementia (FTD)54%

related📖Frontotemporal Dementia (FTD) Genetic Variants54%

related📖Investment Landscape: Frontotemporal Dementia54%

related📖TMEM106B Genetic Modifiers in FTD54%

related📖c9orf72-als-ftd-phenotype-mechanism54%

related📖C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%

related📖GRN Carrier Resilience: Why Some Mutation Carriers Remain As54%

related📖Progranulin Replacement Therapy for FTD — Vector Development54%

related📖Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%

related📖gaps-grn-carrier-resilience-ftd54%

related📖Tau vs TDP-43 Fate Switching in Frontotemporal Dementia54%

related📖TBK1-Mediated Neuroinflammation Hypothesis — Autophagy Failu54%

related📖payload-progranulin-restoration-therapy-ftd54%

related📖Frontotemporal Dementia (FTD) Investment Landscape54%

related📖AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison54%

related📖Behavioral Variant FTD: Network and Molecular Mechanisms54%

related📖C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS and F54%

related📖CBS-FTD Overlap Syndrome54%

related📖CHCHD10 Mitochondrial Dysfunction — ALS/FTD Causal Chain54%

related📖Frontal and Temporal Lobe Selective Vulnerability in FTD54%

related📖FUS Proteinopathy in Frontotemporal Dementia54%

related📖Ion Channel Dysfunction in Frontotemporal Dementia54%

related📖Tau Pathology Pathway in Frontotemporal Dementia54%

related📖GRN Progranulin FTD Causal Chain54%

related📖Microglia in Frontotemporal Dementia Progression54%

related📖Mitochondrial Dysfunction in ALS-FTD Spectrum54%

related📖Neuroimmune Dysfunction in Frontotemporal Dementia54%

related📖Progranulin Haploinsufficiency in Frontotemporal Dementia54%

related📖Semantic Variant PPA: Mechanisms of Language Network Degener54%

related📖Stress Granule Homeostasis in ALS/FTD54%

related📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain54%

related📖TBK1-Mediated Neuroinflammation Hypothesis — Impaired Autoph54%

related📖TREM2 in Frontotemporal Dementia54%

related📖TREM2 in FTD54%

related📖VCP→TDP-43→ALS/FTD Causal Chain54%

related📖BCI for FTD Behavioral Circuit Modulation54%

related📖Frontotemporal Dementia (FTD) Treatment54%

related📖Biomarkers to Distinguish FTLD-tau from FTLD-TDP54%

related📖FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%

related📖FTLD-TDP Subtypes and Mechanisms54%

related📖Update TDP-43 protein page with comprehensive content54%

mentions📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)50%

mentions📖China Neurodegeneration Epidemiology50%

mentions📖DALY Methodology — Neurodegeneration50%

mentions📖Disease Progression & Staging in Neurodegeneration50%

mentions📖Economic Burden — Neurodegeneration50%

mentions📖European Neurodegeneration Epidemiology50%

mentions📖Familial vs Sporadic Neurodegeneration Comparison50%

mentions📖Global Neurodegeneration Epidemiology50%

mentions📖India Neurodegeneration Epidemiology50%

mentions📖Japan Neurodegeneration Epidemiology50%

mentions📖Manganese-Related Neurodegeneration (Manganism)50%

mentions📖mitochondrial-dysfunction-neurodegeneration-comparison50%

mentions📖Mitochondrial Diseases and Neurodegeneration Comparison Matr50%

mentions📖Mitochondrial Membrane Protein-Associated Neurodegeneration 50%

mentions📖Neurodegeneration with Brain Iron Accumulation (NBIA)50%

mentions📖Neurodegeneration50%

mentions📖Potential Impact Measures — Neurodegeneration50%

mentions📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)50%

mentions📖PLA2G6-Associated Neurodegeneration (PLAN)50%

mentions📖Sleep Disorders in Neurodegeneration50%

mentions📖US Neurodegeneration Epidemiology50%

mentions📖therapeutics50%

related📖Liquid Biopsy Diagnostics for Corticobasal Syndrome50%

related📖Liquid Biopsy in Neurodegeneration50%

related📖Cortical Basket Cells (Pyramidal-Targeting)50%

related📖cerebral-small-vessel-disease50%

related📖ALZ-801 Phase 3 APOLLOE4 Extension Trial50%

related📖amdx-2011p-alzheimers-phase-250%

related📖AMDX-2011P Phase 2 Trial for Alzheimer's Disease50%

related📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05650%

related📖Ban2401 Phase 2b Trial (201 Study)50%

related📖Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT062250%

related📖Bepranemab — Phase 2 for PSP50%

related📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease50%

related📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease50%

related📖Buntanetap Phase 3 Parkinson's Disease Trial (NCT07284750%

related📖Centella asiatica Phase 1 Trial for Alzheimer's Disease50%

related📖CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD50%

related📖CpG1018 TLR9 Agonist Phase 1 Trial (NCT05606341)50%

related📖CVN424 Phase 3 ARISE Trial for Parkinson's Disease50%

related📖DAOIBplusAO Phase 2 (NCT06467539) - Novel Antioxidant Augmen50%

related📖Digital Therapeutic Platform for Swallowing and Drooling Pro50%

related📖DNL628 Phase 1 AD Trial (NCT07328451) — Denali Tau ASO50%

related📖E2814 — Phase 2 for 4R-Tauopathy50%

related📖EC5026 (STEP Study) Phase 1 Parkinson's Disease Trial (50%

related📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer50%

related📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea50%

related📖flornaptitril-pet-phase-3-nct0625446950%

related📖FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear 50%

related📖Foralumab Phase 2 Trial for Alzheimer's Disease50%

related📖GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy50%

related📖GTX-102 (GeneTx/Ultragenyx) — Angelman Syndrome Phase 1/2 Tr50%

related📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas50%

related📖gv971-sodium-oligomannurarate-phase-3-nct0590869550%

related📖Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for A50%

related📖IPAT Study Phase 2 (NCT05331144)50%

related📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D50%

related📖KarXT Phase 3 AD Agitation (NCT06585787)50%

related📖KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD 50%

related📖KP405 Phase 1 PD trial (NCT06189170)50%

related📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise50%

related📖Lenrispodun Phase 2 PD Trial (NCT05766813)50%

related📖LHP588: P. gingivalis Targeting for Alzheimer's Disease50%

related📖lipus-brain-phase-3-ad-nct0598357550%

related📖Lithium for PSP/CBS — Phase 2 Trial50%

related📖LY03020 - Luye Pharma Phase 1 Trial50%

related📖LY-3372689 LOTUS Trial - Phase 2 in Progressive Supranuclear50%

related📖LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's Dise50%

related📖LY4006895 Phase 1 Trial - Early Alzheimer's50%

related📖LY4006896 Phase 1 Parkinson's Disease Trial50%

related📖MAR Polypill Phase 2 Alzheimer's Trial (NCT06597058)50%

related📖Metformin for Parkinson's Disease - Phase 2/3 Trial (NC50%

related📖Mevidalen (LY3154207) Phase 2 — NCT0653811650%

related📖MK-1167 Phase 2 AD Trial (MK-1167-008)50%

related📖MK-1167 Phase 2 Alzheimer's Disease Trial50%

related📖MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)50%

related📖ML-007C-MA Phase 2 AD Psychosis (NCT06887192)50%

related📖Gabapentin Enacarbil Phase 4 Trial - Nighttime Agitation50%

related📖Phase 3 Study to Compare the Efficacy and Safety of Masitini50%

related📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE50%

related📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M50%

related📖Semaglutide Phase 3 Alzheimer's Trial (EVOKE, NCT04777350%

related📖Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT050%

related📖Allopregnanolone Regenerative Therapeutic (NCT04838301)50%

related📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M50%

related📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-50%

related📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C50%

related📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)50%

related📖Donanemab Dosing Regimens Phase 3 for Early Alzheimer's50%

related📖Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)50%

related📖Flornaptitril PET Imaging - Phase 3 (NCT06254469)50%

related📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial50%

related📖Remternetug Phase 3 Alzheimer's Trial (NCT06653153)50%

related📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par50%

related📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St50%

related📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451650%

related📖Prasinezumab Phase 3 Parkinson's Disease Trial (NCT071750%

related📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)50%

related📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer50%

related📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'50%

related📖Exciva Alzheimer's Disease Phase 2/3 Trial50%

related📖Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)50%

related📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe50%

related📖NTRX-07 Phase 2 (NCT07058688) - NeuroTherapia cholinergic an50%

related📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD50%

related📖PI-2620 Tau PET Phase 3 - NCT0564168850%

related📖PRI-002 (PRImus-AD) Phase 2 Trial50%

related📖RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT0463905050%

related📖RO7269162 Tau Biomarker Phase 2 (NCT06402838)50%

related📖Recombinant Human Serum Albumin Phase 1 AD (NCT06489015)50%

related📖STK-001 (Stoke Therapeutics) — Dravet Syndrome Phase 1/2 Tri50%

related📖TB006 Phase 2a Parkinson's Disease Trial (NCT06773962)50%

related📖Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT0717050%

related📖TTYP01 Phase 2 Alzheimer's Disease Trial50%

related📖VY7523 Phase 1/2 Alzheimer's Disease Trial50%

related📖Xanamem Phase 2 Alzheimer's Trial (NCT06125951)50%

related📖Alzheimer's Disease Mitochondria-Targeting Companies50%

related📖AD Tau-Targeting Companies50%

related📖Therapeutic Approach Evidence Rankings50%

related📖Therapeutic Mechanism Index50%

related📖PD Botanical and Natural Product Therapeutic Companies50%

related📖Parkinson's Disease Circadian Rhythm Dysfunction Therap50%

related📖Parkinson's Disease DNA Damage Repair Therapeutic Compa50%

related📖PD EGFR and Receptor Tyrosine Kinase Therapeutic Companies50%

related📖PD GBA Glucocerebrosidase Therapeutic Companies50%

related📖PD GPCR Signaling Therapeutic Companies50%

related📖JNK/p38 MAPK Inhibitor Companies for Parkinson's Diseas50%

related📖Parkinson's Disease Synaptic Dysfunction Therapeutic Co50%

related📖PD TREM2 Targeting Companies50%

related📖Ubiquitin-Proteasome System Therapeutic Companies for Parkin50%

related📖Liquid Biopsy Diagnostics for Corticobasal Syndrome50%

related📖Liquid Biopsy in Corticobasal Syndrome50%

related📖Cerebral Small Vessel Disease50%

related📖AAIC 2026 Emerging Therapeutic Targets50%

related📖aaic-2026-novel-therapeutic-targets50%

related📖therapeutic-antibodies50%

related📖AAIC 2026: Therapeutic Approaches50%

related📖AD/PD 2026 Emerging Therapeutic Targets50%

related📖CTAD 2026: Amyloid-Targeting Antibody Trial Results50%

related📖4R-Tau Targeting Therapies for PSP and CBS50%

related📖AAV-LRRK2 IND-Enabling Study Design50%

related📖Metabolic Pathway-Targeted Therapy in ALS50%

related📖Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 50%

related📖Cholinergic System Dysfunction in DLB — Mechanisms and Thera50%

related📖Down Syndrome Alzheimer's Disease: Mechanisms and Thera50%

related📖Environmental Exposure Causal Attribution in ALS — Experimen50%

related📖Epigenetic Dysregulation in Huntington's Disease — Ther50%

related📖ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De50%

related📖Frontal and Temporal Lobe Selective Vulnerability in FTD — M50%

related📖Levodopa-Induced Dyskinesias Mechanism — Experiment Design50%

related📖Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson50%

related📖AAV-LRRK2 Gene Therapy IND-Enabling Study Design50%

related📖Macroautophagy Dysfunction in PD - Experiment Design50%

related📖Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 50%

related📖Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 50%

related📖Microbiome-Gut Barrier Signatures in ALS — Experiment Design50%

related📖N-of-1 Clinical Trial Design for CBS/PSP50%

related📖Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper50%

related📖prion-therapeutic-development50%

related📖Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#50%

related📖Sex Differences in Alzheimer's Disease — mechanisms and50%

related📖Sleep and Respiratory Network Interaction in ALS — Experimen50%

related📖Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo50%

related📖TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an50%

related📖TREM2 Agonist Therapy for Parkinson's Disease — Experim50%

related📖TREM2 Function in Alzheimer's Disease — From Risk Varia50%

related📖Viral Infections and Alzheimer's Disease — causal mecha50%

related📖Viral and Post-Infectious Mechanisms in ALS — Experiment Des50%

related📖Wilson Disease Neurodegeneration: Mechanism and Therapeutic 50%

related📖SNRPA — Small Nuclear Ribonucleoprotein Polypeptide A50%

related📖SNRNP200 (Small Nuclear Ribonucleoprotein 200)50%

related📖SNRPA1 — Small Nuclear Ribonucleoprotein Polypeptide A150%

related📖SNRPB — Small Nuclear Ribonucleoprotein Polypeptide B50%

related📖SUMO1 — Small Ubiquitin-Like Modifier 150%

related📖SUMO2 — Small Ubiquitin-Like Modifier 250%

related📖Alzheimer's Disease Neuropathology is Defined by the Ac50%

related📖Therapeutic Hypothesis: TDP-43 and a-synuclein pathologies i50%

related📖Autophagy-Targeting Chimera (AUTOTAC) Therapy50%

related📖C9orf72 RNA-Targeting Dipeptide Repeat Reduction50%

related📖Gut-Microbiome-Targeted Therapeutic50%

related📖msa-therapeutic-ideas50%

related📖4R-Tau Targeting Therapy for PSP50%

related📖AAV-Delivered RNA Targeting Therapy for Neurodegeneration50%

related📖Autonomic Dysfunction Targeting Therapy for MSA50%

related📖FUS Protein-Targeting Therapy for ALS/FTD50%

related📖payload-ketone-body-therapeutic-strategy50%

related📖4R-Tau Targeting Therapy for PSP50%

related📖Liquid Biopsy in Corticobasal Syndrome50%

related📖AD Therapeutic Approaches Ranked Scorecard50%

related📖ALS Therapeutic Scorecard50%

related📖Amyloid-Beta Clearance Therapeutic Pathways50%

related📖AUTOTAC: Autophagy-Targeting Chimera for Neurodegeneration50%

related📖Axonopathy Mechanisms and Therapeutic Targets50%

related📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for50%

related📖Biomarker-Therapeutic Development Nexus50%

related📖Brain Region Therapeutic Targeting Index50%

related📖Network Degeneration and Pathological Spreading in Corticoba50%

related📖Cerebral Small Vessel Disease in Neurodegeneration50%

related📖Cerebral Small Vessel Disease Mechanisms in Neurodegeneratio50%

related📖Emerging Therapeutic Directions50%

related📖Emerging Therapeutic Directions 2025-202650%

related📖Exosome-Mediated Pathological Protein Propagation50%

related📖fus-phase-separation-neurodegeneration50%

related📖GADD45G as Pathological Sensor: Orchestrating Reactive Glios50%

related📖Geniposide for Alzheimer's disease - immune biomarker t50%

related📖HD Therapeutic Approaches Ranked Scorecard50%

related📖Kinase Targeting for Neurodegenerative Diseases50%

related📖Liquid-Liquid Phase Separation50%

related📖LRRK2 Kinase Inhibition in Parkinson's Disease - Therap50%

related📖Novel Therapeutic Modalities Synthesis50%

related📖NRTI Immunomodulation in Alzheimer's Disease: Molecular50%

related📖PD Therapeutic Scorecard50%

related📖Phase 3 Trial Readiness Matrix — Neurodegenerative Therapeut50%

related📖Protein Phase Separation in Neurodegeneration50%

related📖Protein Phase Separation in Parkinson's Disease50%

related📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P50%

related📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa50%

related📖PSP Therapeutic Response Monitoring and Biomarkers50%

related📖Cellular Senescence Therapeutic Targeting50%

related📖Sleep and Circadian Therapeutic Intervention Synthesis50%

related📖Small-Molecule Derivatives in Neurodegenerative Pathways50%

related📖Target Family Consolidation Analysis — Cross-Disease Therape50%

related📖Therapeutic Approach Evidence Rankings50%

related📖Therapeutic Development Failure Mode Analysis Synthesis50%

related📖Therapeutic Safety Adverse Event Investment Synthesis50%

related📖Therapeutic Synergy and Combination Approach Rankings50%

related📖Therapeutic Targetability Rankings50%

related📖Therapeutic Targets in Neurodegeneration50%

related📖Therapeutic Timing Windows in Neurodegeneration50%

related📖TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th50%

related📖TREM2 in Parkinson's Disease — Cross-Disease Therapeuti50%

related📖KCNN3 Protein (Small Conductance Calcium-Activated Potassium50%

related📖KCNN4 Protein (Small Conductance Calcium-Activated Potassium50%

related📖SUMO1 Protein - Small Ubiquitin-Like Modifier 150%

related📖SUMO2 Protein - Small Ubiquitin-Like Modifier 250%

related📖Dr. Marcus J. C. Cook — Tauopathy Clinical Trial Design50%

related📖Cross-Disease Therapeutic Targets in 4R-Tauopathies50%

related📖AD/PD Therapeutic Target Comparison Matrix50%

related📖AD Therapeutic Approaches Scorecard - 28 Approaches Ranked50%

related📖Alpha-Synuclein-Targeting Therapies50%

related📖ALS Therapeutic Landscape — Programs by Phase and Modality50%

related📖Therapeutic Antibody Comparison Matrix50%

related📖asm-inhibitors-small-biotech50%

related📖ATP13A2 (PARK9) Targeting for Parkinson's Disease50%

related📖Blood-Brain Barrier Dysfunction and Therapeutic Strategies i50%

related📖CVN424 Phase 3 Trial for Parkinson's Disease50%

related📖Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP50%

related📖FTD Therapeutic Landscape50%

related📖FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis50%

related📖GBA-Targeting Therapies50%

related📖Inotersen (Tegsedi) - Therapeutic Overview50%

related📖Kinase and Phosphatase Therapeutic Target Matrix50%

related📖LRRK2 Kinase-Targeting Therapies50%

related📖LRRK2-Targeting Therapies50%

related📖N-of-1 and Personalized Clinical Trial Design for CBS/PSP50%

related📖Neurodegeneration Therapeutic Target Comparison Matrix50%

related📖Neurogenesis-Targeting Therapies for Neurodegenerative Disea50%

related📖Neuroinflammation Targeting Therapies50%

related📖PD Therapeutic Approaches Scorecard50%

related📖PSP/CBS Therapeutic Target Index50%

related📖PSP Therapeutic Ideas50%

related📖RNA-Targeting Therapies for Neurodegenerative Diseases50%

related📖RNA Targeting Therapy for Neurodegeneration50%

related📖section-197-advanced-clinical-trial-design-cbs-psp50%

related📖Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Ta50%

related📖Small Molecule Drugs for Neurodegenerative Diseases50%

related📖Small Molecule Therapies in Neurodegenerative Diseases50%

related📖SOD1-Targeting Therapies for ALS50%

related📖Tau Small-Molecule Therapeutics50%

related📖Therapeutic Modalities in Neurodegeneration50%

related📖Therapeutic Targets Index50%

related📖TREM2-Targeting Therapies50%

related📖VPS35 Retromer Targeting Therapies50%

mentions📖cerebral-small-vessel-disease40%

mentions📖Cerebral Small Vessel Disease40%

mentions📖SNRPA — Small Nuclear Ribonucleoprotein Polypeptide A40%

mentions📖SNRNP200 (Small Nuclear Ribonucleoprotein 200)40%

mentions📖SNRPA1 — Small Nuclear Ribonucleoprotein Polypeptide A140%

mentions📖SNRPB — Small Nuclear Ribonucleoprotein Polypeptide B40%

mentions📖SUMO1 — Small Ubiquitin-Like Modifier 140%

mentions📖SUMO2 — Small Ubiquitin-Like Modifier 240%

mentions📖Cerebral Small Vessel Disease in Neurodegeneration40%

mentions📖Cerebral Small Vessel Disease Mechanisms in Neurodegeneratio40%

mentions📖Small-Molecule Derivatives in Neurodegenerative Pathways40%

mentions📖KCNN3 Protein (Small Conductance Calcium-Activated Potassium40%

mentions📖KCNN4 Protein (Small Conductance Calcium-Activated Potassium40%

mentions📖SUMO1 Protein - Small Ubiquitin-Like Modifier 140%

mentions📖SUMO2 Protein - Small Ubiquitin-Like Modifier 240%

mentions📖asm-inhibitors-small-biotech40%

mentions📖Small Molecule Drugs for Neurodegenerative Diseases40%

mentions📖Small Molecule Therapies in Neurodegenerative Diseases40%

mentions📖Tau Small-Molecule Therapeutics40%

mentions📖AAV-LRRK2 IND-Enabling Study Design40%

mentions📖Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 40%

mentions📖Environmental Exposure Causal Attribution in ALS — Experimen40%

mentions📖ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De40%

mentions📖Levodopa-Induced Dyskinesias Mechanism — Experiment Design40%

mentions📖AAV-LRRK2 Gene Therapy IND-Enabling Study Design40%

mentions📖Macroautophagy Dysfunction in PD - Experiment Design40%

mentions📖Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 40%

mentions📖Microbiome-Gut Barrier Signatures in ALS — Experiment Design40%

mentions📖N-of-1 Clinical Trial Design for CBS/PSP40%

mentions📖Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper40%

mentions📖Sleep and Respiratory Network Interaction in ALS — Experimen40%

mentions📖TREM2 Agonist Therapy for Parkinson's Disease — Experim40%

mentions📖Viral and Post-Infectious Mechanisms in ALS — Experiment Des40%

mentions📖Dr. Marcus J. C. Cook — Tauopathy Clinical Trial Design40%

mentions📖N-of-1 and Personalized Clinical Trial Design for CBS/PSP40%

mentions📖section-197-advanced-clinical-trial-design-cbs-psp40%

mentions📖Liquid Biopsy Diagnostics for Corticobasal Syndrome40%

mentions📖Liquid Biopsy in Neurodegeneration40%

mentions📖Liquid Biopsy Diagnostics for Corticobasal Syndrome40%

mentions📖Liquid Biopsy in Corticobasal Syndrome40%

mentions📖Liquid-Liquid Phase Separation40%

mentions📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa40%

mentions📖Alzheimer's Disease Neuropathology is Defined by the Ac40%

mentions📖Network Degeneration and Pathological Spreading in Corticoba40%

mentions📖Exosome-Mediated Pathological Protein Propagation40%

mentions📖GADD45G as Pathological Sensor: Orchestrating Reactive Glios40%

mentions📖ALZ-801 Phase 3 APOLLOE4 Extension Trial40%

mentions📖amdx-2011p-alzheimers-phase-240%

mentions📖AMDX-2011P Phase 2 Trial for Alzheimer's Disease40%

mentions📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05640%

mentions📖Ban2401 Phase 2b Trial (201 Study)40%

mentions📖Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT062240%

mentions📖Bepranemab — Phase 2 for PSP40%

mentions📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease40%

mentions📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease40%

mentions📖Buntanetap Phase 3 Parkinson's Disease Trial (NCT07284740%

mentions📖Centella asiatica Phase 1 Trial for Alzheimer's Disease40%

mentions📖CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD40%

mentions📖CpG1018 TLR9 Agonist Phase 1 Trial (NCT05606341)40%

mentions📖CVN424 Phase 3 ARISE Trial for Parkinson's Disease40%

mentions📖DAOIBplusAO Phase 2 (NCT06467539) - Novel Antioxidant Augmen40%

mentions📖DNL628 Phase 1 AD Trial (NCT07328451) — Denali Tau ASO40%

mentions📖E2814 — Phase 2 for 4R-Tauopathy40%

mentions📖EC5026 (STEP Study) Phase 1 Parkinson's Disease Trial (40%

mentions📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer40%

mentions📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea40%

mentions📖flornaptitril-pet-phase-3-nct0625446940%

mentions📖FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear 40%

mentions📖Foralumab Phase 2 Trial for Alzheimer's Disease40%

mentions📖GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy40%

mentions📖GTX-102 (GeneTx/Ultragenyx) — Angelman Syndrome Phase 1/2 Tr40%

mentions📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas40%

mentions📖gv971-sodium-oligomannurarate-phase-3-nct0590869540%

mentions📖Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for A40%

mentions📖IPAT Study Phase 2 (NCT05331144)40%

mentions📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D40%

mentions📖KarXT Phase 3 AD Agitation (NCT06585787)40%

mentions📖KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD 40%

mentions📖KP405 Phase 1 PD trial (NCT06189170)40%

mentions📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise40%

mentions📖Lenrispodun Phase 2 PD Trial (NCT05766813)40%

mentions📖lipus-brain-phase-3-ad-nct0598357540%

mentions📖Lithium for PSP/CBS — Phase 2 Trial40%

mentions📖LY03020 - Luye Pharma Phase 1 Trial40%

mentions📖LY-3372689 LOTUS Trial - Phase 2 in Progressive Supranuclear40%

mentions📖LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's Dise40%

mentions📖LY4006895 Phase 1 Trial - Early Alzheimer's40%

mentions📖LY4006896 Phase 1 Parkinson's Disease Trial40%

mentions📖MAR Polypill Phase 2 Alzheimer's Trial (NCT06597058)40%

mentions📖Metformin for Parkinson's Disease - Phase 2/3 Trial (NC40%

mentions📖Mevidalen (LY3154207) Phase 2 — NCT0653811640%

mentions📖MK-1167 Phase 2 AD Trial (MK-1167-008)40%

mentions📖MK-1167 Phase 2 Alzheimer's Disease Trial40%

mentions📖MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)40%

mentions📖ML-007C-MA Phase 2 AD Psychosis (NCT06887192)40%

mentions📖Gabapentin Enacarbil Phase 4 Trial - Nighttime Agitation40%

mentions📖Phase 3 Study to Compare the Efficacy and Safety of Masitini40%

mentions📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE40%

mentions📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M40%

mentions📖Semaglutide Phase 3 Alzheimer's Trial (EVOKE, NCT04777340%

mentions📖Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT040%

mentions📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M40%

mentions📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-40%

mentions📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C40%

mentions📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)40%

mentions📖Donanemab Dosing Regimens Phase 3 for Early Alzheimer's40%

mentions📖Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)40%

mentions📖Flornaptitril PET Imaging - Phase 3 (NCT06254469)40%

mentions📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial40%

mentions📖Remternetug Phase 3 Alzheimer's Trial (NCT06653153)40%

mentions📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par40%

mentions📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St40%

mentions📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451640%

mentions📖Prasinezumab Phase 3 Parkinson's Disease Trial (NCT071740%

mentions📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)40%

mentions📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer40%

mentions📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'40%

mentions📖Exciva Alzheimer's Disease Phase 2/3 Trial40%

mentions📖Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)40%

mentions📖NTRX-07 Phase 2 (NCT07058688) - NeuroTherapia cholinergic an40%

mentions📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD40%

mentions📖PI-2620 Tau PET Phase 3 - NCT0564168840%

mentions📖PRI-002 (PRImus-AD) Phase 2 Trial40%

mentions📖RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT0463905040%

mentions📖RO7269162 Tau Biomarker Phase 2 (NCT06402838)40%

mentions📖Recombinant Human Serum Albumin Phase 1 AD (NCT06489015)40%

mentions📖STK-001 (Stoke Therapeutics) — Dravet Syndrome Phase 1/2 Tri40%

mentions📖TB006 Phase 2a Parkinson's Disease Trial (NCT06773962)40%

mentions📖Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT0717040%

mentions📖TTYP01 Phase 2 Alzheimer's Disease Trial40%

mentions📖VY7523 Phase 1/2 Alzheimer's Disease Trial40%

mentions📖Xanamem Phase 2 Alzheimer's Trial (NCT06125951)40%

mentions📖Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#40%

mentions📖fus-phase-separation-neurodegeneration40%

mentions📖Phase 3 Trial Readiness Matrix — Neurodegenerative Therapeut40%

mentions📖Protein Phase Separation in Neurodegeneration40%

mentions📖Protein Phase Separation in Parkinson's Disease40%

mentions📖ALS Therapeutic Landscape — Programs by Phase and Modality40%

mentions📖CVN424 Phase 3 Trial for Parkinson's Disease40%

mentions📖Cortical Basket Cells (Pyramidal-Targeting)40%

mentions📖LHP588: P. gingivalis Targeting for Alzheimer's Disease40%

mentions📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe40%

mentions📖Alzheimer's Disease Mitochondria-Targeting Companies40%

mentions📖AD Tau-Targeting Companies40%

mentions📖PD TREM2 Targeting Companies40%

mentions📖CTAD 2026: Amyloid-Targeting Antibody Trial Results40%

mentions📖4R-Tau Targeting Therapies for PSP and CBS40%

mentions📖Metabolic Pathway-Targeted Therapy in ALS40%

mentions📖Epigenetic Dysregulation in Huntington's Disease — Ther40%

mentions📖Autophagy-Targeting Chimera (AUTOTAC) Therapy40%

mentions📖C9orf72 RNA-Targeting Dipeptide Repeat Reduction40%

mentions📖4R-Tau Targeting Therapy for PSP40%

mentions📖AAV-Delivered RNA Targeting Therapy for Neurodegeneration40%

mentions📖Autonomic Dysfunction Targeting Therapy for MSA40%

mentions📖FUS Protein-Targeting Therapy for ALS/FTD40%

mentions📖4R-Tau Targeting Therapy for PSP40%

mentions📖AUTOTAC: Autophagy-Targeting Chimera for Neurodegeneration40%

mentions📖Brain Region Therapeutic Targeting Index40%

mentions📖Geniposide for Alzheimer's disease - immune biomarker t40%

mentions📖Kinase Targeting for Neurodegenerative Diseases40%

mentions📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P40%

mentions📖Cellular Senescence Therapeutic Targeting40%

mentions📖Alpha-Synuclein-Targeting Therapies40%

mentions📖ATP13A2 (PARK9) Targeting for Parkinson's Disease40%

mentions📖Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP40%

mentions📖FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis40%

mentions📖GBA-Targeting Therapies40%

mentions📖LRRK2 Kinase-Targeting Therapies40%

mentions📖LRRK2-Targeting Therapies40%

mentions📖Neurogenesis-Targeting Therapies for Neurodegenerative Disea40%

mentions📖Neuroinflammation Targeting Therapies40%

mentions📖RNA-Targeting Therapies for Neurodegenerative Diseases40%

mentions📖RNA Targeting Therapy for Neurodegeneration40%

mentions📖Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Ta40%

mentions📖SOD1-Targeting Therapies for ALS40%

mentions📖TREM2-Targeting Therapies40%

mentions📖VPS35 Retromer Targeting Therapies40%

mentions📖Digital Therapeutic Platform for Swallowing and Drooling Pro40%

mentions📖Allopregnanolone Regenerative Therapeutic (NCT04838301)40%

mentions📖Therapeutic Approach Evidence Rankings40%

mentions📖Therapeutic Mechanism Index40%

mentions📖PD Botanical and Natural Product Therapeutic Companies40%

mentions📖Parkinson's Disease Circadian Rhythm Dysfunction Therap40%

mentions📖Parkinson's Disease DNA Damage Repair Therapeutic Compa40%

mentions📖PD EGFR and Receptor Tyrosine Kinase Therapeutic Companies40%

mentions📖PD GBA Glucocerebrosidase Therapeutic Companies40%

mentions📖PD GPCR Signaling Therapeutic Companies40%

mentions📖JNK/p38 MAPK Inhibitor Companies for Parkinson's Diseas40%

mentions📖Parkinson's Disease Synaptic Dysfunction Therapeutic Co40%

mentions📖Ubiquitin-Proteasome System Therapeutic Companies for Parkin40%

mentions📖AAIC 2026 Emerging Therapeutic Targets40%

mentions📖aaic-2026-novel-therapeutic-targets40%

mentions📖therapeutic-antibodies40%

mentions📖AAIC 2026: Therapeutic Approaches40%

mentions📖AD/PD 2026 Emerging Therapeutic Targets40%

mentions📖Cholinergic System Dysfunction in DLB — Mechanisms and Thera40%

mentions📖Down Syndrome Alzheimer's Disease: Mechanisms and Thera40%

mentions📖Frontal and Temporal Lobe Selective Vulnerability in FTD — M40%

mentions📖Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson40%

mentions📖Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 40%

mentions📖prion-therapeutic-development40%

mentions📖Sex Differences in Alzheimer's Disease — mechanisms and40%

mentions📖Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo40%

mentions📖TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an40%

mentions📖TREM2 Function in Alzheimer's Disease — From Risk Varia40%

mentions📖Viral Infections and Alzheimer's Disease — causal mecha40%

mentions📖Wilson Disease Neurodegeneration: Mechanism and Therapeutic 40%

mentions📖Therapeutic Hypothesis: TDP-43 and a-synuclein pathologies i40%

mentions📖Gut-Microbiome-Targeted Therapeutic40%

mentions📖msa-therapeutic-ideas40%

mentions📖payload-ketone-body-therapeutic-strategy40%

mentions📖AD Therapeutic Approaches Ranked Scorecard40%

mentions📖ALS Therapeutic Scorecard40%

mentions📖Amyloid-Beta Clearance Therapeutic Pathways40%

mentions📖Axonopathy Mechanisms and Therapeutic Targets40%

mentions📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for40%

mentions📖Biomarker-Therapeutic Development Nexus40%

mentions📖Emerging Therapeutic Directions40%

mentions📖Emerging Therapeutic Directions 2025-202640%

mentions📖HD Therapeutic Approaches Ranked Scorecard40%

mentions📖LRRK2 Kinase Inhibition in Parkinson's Disease - Therap40%

mentions📖Novel Therapeutic Modalities Synthesis40%

mentions📖NRTI Immunomodulation in Alzheimer's Disease: Molecular40%

mentions📖PD Therapeutic Scorecard40%

mentions📖PSP Therapeutic Response Monitoring and Biomarkers40%

mentions📖Sleep and Circadian Therapeutic Intervention Synthesis40%

mentions📖Target Family Consolidation Analysis — Cross-Disease Therape40%

mentions📖Therapeutic Approach Evidence Rankings40%

mentions📖Therapeutic Development Failure Mode Analysis Synthesis40%

mentions📖Therapeutic Safety Adverse Event Investment Synthesis40%

mentions📖Therapeutic Synergy and Combination Approach Rankings40%

mentions📖Therapeutic Targetability Rankings40%

mentions📖Therapeutic Targets in Neurodegeneration40%

mentions📖Therapeutic Timing Windows in Neurodegeneration40%

mentions📖TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th40%

mentions📖TREM2 in Parkinson's Disease — Cross-Disease Therapeuti40%

mentions📖Cross-Disease Therapeutic Targets in 4R-Tauopathies40%

mentions📖AD/PD Therapeutic Target Comparison Matrix40%

mentions📖AD Therapeutic Approaches Scorecard - 28 Approaches Ranked40%

mentions📖Therapeutic Antibody Comparison Matrix40%

mentions📖Blood-Brain Barrier Dysfunction and Therapeutic Strategies i40%

mentions📖FTD Therapeutic Landscape40%

mentions📖Inotersen (Tegsedi) - Therapeutic Overview40%

mentions📖Kinase and Phosphatase Therapeutic Target Matrix40%

mentions📖Neurodegeneration Therapeutic Target Comparison Matrix40%

mentions📖PD Therapeutic Approaches Scorecard40%

mentions📖PSP/CBS Therapeutic Target Index40%

mentions📖PSP Therapeutic Ideas40%

mentions📖Therapeutic Modalities in Neurodegeneration40%

mentions📖Therapeutic Targets Index40%

related📖C9orf72 — Chromosome 9 Open Reading Frame 7240%

related📖HSP70 Gene40%

related📖HSP70 Inducer Therapies for Neurodegeneration40%

related📖c9orf7240%

related📖HSP70 (Heat Shock Protein 70 / HSPA1A)40%

related📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)40%

related📖Tau Protein40%

related📖CSF1R — Colony Stimulating Factor 1 Receptor40%

related📖PARP1 Gene40%

related📖CSF1R Protein (Colony Stimulating Factor 1 Receptor)40%

related📖PARP1 (Poly(ADP-Ribose) Polymerase 1)40%

related📖G3BP140%

related📖HSPA1A Gene40%

related📖HSPA1A Protein40%

related📖TGM2 — Transglutaminase 240%

related📖TARDBP — TAR DNA Binding Protein 4340%

related📖tardbp40%

related📖cell-types-sod1-mutant-motor-neurons40%

related📖entities-sod140%

related📖SOD1 Protein (Superoxide Dismutase 1)40%

related📖sod140%

related📖SOD1 Protein40%